Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR – Get Free Report) has received an average rating of “Hold” from the five ratings firms that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $38.67.
Several research analysts have recently weighed in on PHAR shares. Oppenheimer restated an “outperform” rating on shares of Pharming Group in a research note on Thursday, July 30th. HC Wainwright reissued a “buy” rating and issued a $37.00 target price on shares of Pharming Group in a research report on Tuesday, September 22nd. Zacks Research downgraded shares of Pharming Group from a “hold” rating to a “strong sell” rating in a report on Friday, July 31st. Canaccord Genuity Group set a $38.00 target price on shares of Pharming Group in a research note on Wednesday, September 23rd. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Pharming Group in a research note on Friday, August 7th.
Get Our Latest Report on Pharming Group
Hedge Funds Weigh In On Pharming Group
Pharming Group Stock Performance
Shares of PHAR opened at $9.75 on Friday. The company has a quick ratio of 2.31, a current ratio of 3.01 and a debt-to-equity ratio of 0.34. The stock has a market cap of $690.11 million, a P/E ratio of 81.25 and a beta of -0.05. The business’s 50 day moving average price is $11.15 and its 200-day moving average price is $13.26. Pharming Group has a 52 week low of $9.62 and a 52 week high of $21.34.
Pharming Group (NASDAQ:PHAR – Get Free Report) last released its earnings results on Thursday, July 30th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.06 by ($0.04). Pharming Group had a return on equity of 3.40% and a net margin of 2.51%. Equities research analysts anticipate that Pharming Group will post 0.22 earnings per share for the current fiscal year.
About Pharming Group
Pharming Group N.V. is a global biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and conditions with significant unmet medical needs, using biotechnology and protein-replacement approaches.
Pharming’s commercial products include Ruconest (conestat alfa), a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, and Joenja (leniolisib), an oral therapy for activated phosphoinositide 3-kinase delta syndrome, a rare primary immunodeficiency disorder.
Further Reading
- Five stocks we like better than Pharming Group
- Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?
- The AI Buildout Needs Power It Cannot Get: 4 Energy Stocks Already Have It
- McDonald’s Is Undergoing a Massive New Growth Strategy. Can It Win Back Consumers?
- MGM Resorts Stock Sinks After Diller Deal Collapse: Overreaction or Warning?
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.
